Quarterly report pursuant to Section 13 or 15(d)

Royalty and Commercial Payment Purchase Agreements - Affitech (Details)

v3.22.1
Royalty and Commercial Payment Purchase Agreements - Affitech (Details) - USD ($)
$ in Thousands
 3 Months Ended 12 Months Ended
Jan. 28, 2022
Oct. 06, 2021
Mar. 31, 2022
Dec. 31, 2021
Agreements        
Long-term royalty and commercial payment receivables     $ 69,075 $ 69,075
Contingent consideration under RPAs and CPPAs     3,075 8,075
Impairment of long-term royalty receivable     0 $ 0
Affitech | Commercial payment purchase agreement        
Agreements        
Upfront payment   $ 6,000    
Payments eligible to receive (as a percent) 0.50% 0.50%    
Commercial payment receivable term 10 years 10 years    
Maximum additional payments upon achievement of regulatory and sales milestones   $ 20,000    
Long-term royalty and commercial payment receivables   14,000    
Maximum payable on regulatory milestone   8,000    
Maximum payable on sales milestone   12,000    
Contingent consideration under RPAs and CPPAs   8,000 3,000  
Milestone payment $ 5,000      
Maximum payable on regulatory milestone, Additional amount 3,000      
Maximum payable on sales milestone, Additional amount $ 12,000      
Impairment of long-term royalty receivable     0  
Affitech | Commercial payment purchase agreement | Regulatory milestones        
Agreements        
Contingent consideration under RPAs and CPPAs   $ 8,000 3,000  
Affitech | Commercial payment purchase agreement | Sales milestones        
Agreements        
Contingent consideration under RPAs and CPPAs     $ 0